The Claim
In adults with biopsy-proven non-alcoholic fatty liver disease, the addition of portal lymphadenopathy status to the APRI fibrosis score increases the diagnostic accuracy for advanced fibrosis compared to the APRI fibrosis score alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with confirmed non-alcoholic fatty liver disease, combining portal lymphadenopathy status with the APRI fibrosis score improves the ability to correctly identify advanced liver fibrosis compared to using the APRI score alone.
See the scientific wording
In adults with biopsy-proven non-alcoholic fatty liver disease, adding portal lymphadenopathy status to the APRI fibrosis score improves its diagnostic accuracy for advanced fibrosis, suggesting it may enhance non-invasive risk stratification.
When the liver is damaged by fat buildup, immune cells gather near the liver and cause nearby lymph nodes to swell. These swollen lymph nodes show that the body is reacting strongly to the damage, and this strong reaction also makes the liver scar more. Adding this swelling to a blood test helps tell if the scarring is severe because both the swelling and the scarring come from the same underlying immune response.
What the research says
1 studyScientists found that when people with fatty liver disease have enlarged lymph nodes near the liver, it often means their liver scarring is worse. Adding this simple scan finding to a common blood test makes the test better at spotting serious liver damage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.